Q2 2026 13F · SEC CIK 2050709

Squadron Capital Management LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $292.1M
Reported positions: 34
Holdings vs S&P 500, 3 yrs: —
Assets under management: $385.7M

Squadron Capital Management LLC is a hedge fund that reported 34 positions worth $292.1M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Relmada Therapeutics Inc (RLMD, 17.4%), C4 Therapeutics Inc (CCCC, 11.5%), Cogent Biosciences Inc (COGT, 11.5%).

Squadron Capital Management LLC holdings all 34 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Squadron Capital Management LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
RLMDRelmada Therapeutics Inc	17.4%	23.6%	7,350,000	-13.3%	$50.9M
CCCCC4 Therapeutics Inc	11.5%	2.4%	7,200,000	+220.0%	$33.6M
COGTCogent Biosciences Inc	11.5%	12.1%	865,000	+9.8%	$33.5M
KODKodiak Sciences Inc	6.7%	5.8%	500,000	+31.6%	$19.5M
RLAYRelay Therapeutics Inc	6.2%	2.7%	970,000	+44.2%	$18.1M
ZNTLZentalis Pharmaceuticals Inc	6.1%	3.4%	3,700,000	+1.9%	$17.9M
EWTXEdgewise Therapeutics Inc	4.0%	4.4%	290,000	-17.1%	$11.8M
MAZEMaze Therapeutics Inc	3.4%	3.1%	335,000	+30.1%	$10.0M
IVAInventiva SA	3.2%	1.2%	2,435,000	+355.1%	$9.2M
ANLAdlai Nortye Ltd	3.0%	3.5%	764,876	-39.5%	$8.8M
ELVNEnliven Therapeutics Inc	2.8%	New	160,000	—	$8.1M
PALIPalisade Bio Inc	2.1%	2.1%	3,000,000	+0.0%	$6.3M
IKTInhibikase Therapeutics Inc	2.1%	2.4%	3,000,000	-14.3%	$6.1M
ADAGAdagene Inc	1.8%	New	1,250,000	—	$5.3M
FBRXForte Biosciences Inc	1.6%	New	225,000	—	$4.8M
N44821101Inflarx NV	1.5%	New	2,000,000	—	$4.5M
ASMBAssembly Biosciences Inc.	1.5%	New	160,000	—	$4.4M
PMNPromis Neurosciences Inc	1.5%	1.7%	324,977	+0.0%	$4.3M
CTNMContineum Therapeutics Inc	1.5%	New	260,000	—	$4.3M
CMPSCompass Pathways PLC	1.5%	New	300,000	—	$4.2M
24477V105Definium Therapeutics Inc	1.4%	New	85,000	—	$4.0M
SLGLSol-Gel Technologies Ltd	1.3%	1.0%	52,000	+67.7%	$3.9M
BIOABioage Labs Inc	1.3%	New	155,000	—	$3.8M
SCYXScynexis Inc	1.1%	New	756,884	—	$3.1M
PRQRProqr Thrapeutics N V	1.0%	New	1,511,496	—	$2.8M
RZLTRezolute, Inc.	0.7%	New	403,410	—	$2.1M
LPCNLipocine Inc New	0.7%	1.4%	810,000	+80.0%	$2.1M
CUECue Biopharma Inc	0.5%	New	50,000	—	$1.6M
CALCCalcimedica Inc	0.4%	New	1,244,864	—	$1.3M
22053A305Quince Therapeutics Inc	0.3%	New	40,375	—	$734K
KTTAPasithea Therapeutics Corp	0.2%	0.6%	1,000,000	-52.4%	$515K
INMInMed Pharmaceuticals Inc	0.2%	New	325,000	—	$504K
NMRANeumora Therapeutics Inc.	0.1%	New	100,000	—	$170K
NXTCNextcure Inc	0.0%	1.1%	64,464	-75.7%	$103K

What Squadron Capital Management LLC bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: —
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$292.1M	34
Q1 2026	$250.0M	30
Q4 2025	$224.1M	29

Questions about Squadron Capital Management LLC's portfolio

What stocks does Squadron Capital Management LLC own?

Squadron Capital Management LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 34 positions worth $292.1M. The largest are Relmada Therapeutics Inc (RLMD) at 17.4%, C4 Therapeutics Inc (CCCC) at 11.5%, Cogent Biosciences Inc (COGT) at 11.5%, Kodiak Sciences Inc (KOD) at 6.7% and Relay Therapeutics Inc (RLAY) at 6.2%.

What did Squadron Capital Management LLC buy last quarter?

In Q2 2026, Squadron Capital Management LLC added a new position in Enliven Therapeutics Inc (ELVN), a new position in Adagene Inc (ADAG), a new position in Forte Biosciences Inc (FBRX), a new position in Inflarx NV, a new position in Assembly Biosciences Inc. (ASMB), Inventiva SA (IVA) (+355.1% shares), C4 Therapeutics Inc (CCCC) (+220.0% shares) and Lipocine Inc New (LPCN) (+80.0% shares), compared with its Q1 2026 filing.

What did Squadron Capital Management LLC sell last quarter?

In Q2 2026, Squadron Capital Management LLC sold all of Kalvista Pharmaceuticals Inc (KALV), sold all of Abivax SA (ABVX), sold all of Nektar Therapeutics (NKTR), sold all of Scynexis Inc (SCYX), sold all of Eupraxia Pharmaceuticals Inc (EPRX), Nextcure Inc (NXTC) (-75.7% shares), Pasithea Therapeutics Corp (KTTA) (-52.4% shares) and Adlai Nortye Ltd (ANL) (-39.5% shares), compared with its Q1 2026 filing.

When is Squadron Capital Management LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Squadron Capital Management LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Squadron Capital Management LLC manage?

Squadron Capital Management LLC reported $385.7M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $292.1M.